
Congratulations to Dr. Khaled Abdelrahman on the recent awarding of a Canada Foundation for Innovation John R. Evans Leaders Fund (JELF) award for The Abdelrahman Lab on the role of GPCRs in Alzheimer’s Disease pathophysiology.
Dr. Abdelrahman’s lab is dedicated to understanding how Alzheimer’s disease disrupts brain function, particularly through its impact on blood flow. The lab focuses on G protein-coupled receptors (GPCRs, the most abundant receptor family in the body, and their interactions with toxic beta-amyloid and tau proteins, which are hallmarks of Alzheimer’s disease. By investigating how these interactions impair GPCR function and contribute to impaired blood flow to the brain, the lab aims to uncover new therapeutic targets.
With support from the CFI-JELF grant, the lab will acquire cutting-edge equipment to conduct advanced experiments using Alzheimer’s brain cells and mouse models. This will enable researchers in Abdelrahman’s group to study how beta-amyloid and tau affect GPCR signaling, brain blood flow, and memory while also exploring sex-based differences in disease progression. Additionally, the lab will test drugs targeting GPCRs to assess their potential in restoring blood flow and improving Alzheimer’s symptoms in both male and female mouse models.
By leveraging innovative tools and techniques, Dr. Abdelrahman’s lab strives uncover the role of GPCRs in Alzheimer’s and accelerate the development of novel treatment strategies for diverse patient populations.














